Vivani Medical, Inc. (VANI) analyst actions
Rating and price-target actions on VANI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VANI overview →
5 measured VANI analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects | Press release | -8.04% | -12.20% | |
| Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management | Press release | +0.83% | -5.79% | |
| Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults | Press release | -5.46% | -3.64% | |
| Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia | Press release | -0.80% | -5.60% | |
| Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia | Press release | -0.93% | -4.66% |
Keep exploring
More VANI: earnings → · SEC filings → · VANI overview →